The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women
Abstract
BACKGROUND: Few strategies are available for the prevention of cognitive impairment in elderly persons. Serum lipoprotein levels may be important predictors of cognitive function, and drugs that lower cholesterol may be effective for the prevention of cognitive impairment. OBJECTIVE: To determine whether serum lipoprotein levels, the 4-year change in serum lipoprotein levels, and the use of statin drugs are associated with cognition in older women without dementia. DESIGN, SETTING, AND PARTICIPANTS: An observational study of 1037 postmenopausal women with coronary heart disease enrolled in the Heart and Estrogen/progestin Replacement Study (participants at 10 of 20 centers). MAIN OUTCOME MEASURE: The Modified Mini-Mental State Examination was administered at the end of the study after 4 years of follow-up. Women whose score was less than 84 points (>1.5 SDs below the mean) were classified as having cognitive impairment. Lipoprotein levels (total, high-density lipoprotein, and low-density lipoprotein [LDL] cholesterol and triglycerides) were measured at baseline and at the end of the study; statin use was documented at each visit. RESULTS: Compared with women in the lower quartiles, women in the highest LDL cholesterol quartile at cognitive testing had worse mean plus minus SD Modified Mini-Mental State Examination scores (93.7 plus minus 6.0 vs 91.9 plus minus 7.6; P =.002) and an increased likelihood of cognitive impairment (adjusted odds ratio, 1.76; 95% confidence interval, 1.04-2.97). A reduction in the LDL cholesterol level during the 4 years tended to be associated with a lower odds of impairment (adjusted odds ratio, 0.61; 95% confidence interval, 0.36-1.03) compared with women whose levels increased. Higher total and LDL cholesterol levels, corrected for lipoprotein(a) levels, were also associated with a worse Modified Mini-Mental State Examination score and a higher likelihood of impairment, whereas high-density lipoprotein cholesterol and triglyceride levels were not associated with cognition. Compared with nonusers, statin users had higher mean plus minus SD Modified Mini-Mental State Examination scores (92.7 plus minus 7.1 vs 93.7 plus minus 6.1; P =.02) and a trend for a lower likelihood of cognitive impairment (odds ratio, 0.67; 95% confidence interval, 0.42-1.05), findings that seemed to be independent of lipid levels. CONCLUSIONS: High LDL and total cholesterol levels are associated with cognitive impairment, and lowering these lipoprotein levels may be a strategy for preventing impairment. The association between statin use and better cognitive function in women without dementia requires further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
(1987) · PubMed · Cited by 2,657
Statins and the risk of dementia
Jick, H., Zornberg, G., Jick, S., Seshadri, S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,759
Wolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398
Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons
Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., & Simons, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6460 · Cited by 1,166
Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Rosenson, R. S., & Tangney, C. C. (1998) · JAMA · doi:10.1001/jama.279.20.1643 · Cited by 954
Yoshitake, T., Kiyohara, Y., Kato, I., Ohmura, T., Iwamoto, H., Nakayama, K., Ohmori, S., Nomiyama, K., Kawano, H., Ueda, K., et al. (1995) · Neurology · doi:10.1212/wnl.45.6.1161 · Cited by 829
Rates and risk factors for dementia and Alzheimer’s disease: Results from EURODEM pooled analyses
Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Amaducci, L. A., Brayne, C., Copeland, J. R. M., Dartigues, J.-F., Kragh-Sorensen, P., et al. (1999) · Neurology · doi:10.1212/wnl.52.1.78 · Cited by 758
Serum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease
Notkola, I.-L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., & Nissinen, A. (1998) · Neuroepidemiology · doi:10.1159/000026149 · Cited by 669
Vascular risk factors for Alzheimer’s disease:
Breteler, M. M. B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00110-4 · Cited by 664
Estimated Prevalence of Alzheimer's Disease in the United States
Evans, D. A. (1990) · The Milbank Quarterly · doi:10.2307/3350099 · Cited by 357
The role of cholesterol in the biosynthesis of β-amyloid.
Frears, E. R., Stephens, D. J., Walters, C. E., Davies, H., & Austen, B. M. (1999) · NeuroReport · doi:10.1097/00001756-199906030-00014 · Cited by 324
Effects of lovastatin on cognitive function and psychological well-being
Muldoon, M. F., Barger, S. D., Ryan, C. M., Flory, J. D., Lehoczky, J. P., Matthews, K. A., & Manuck, S. B. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00353-3 · Cited by 290
Heart and Estrogen/progestin Replacement Study (HERS)
Grady, D., Applegate, W., Bush, T., Furberg, C., Riggs, B., & Hulley, S. B. (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(98)00010-5 · Cited by 260
Self-citationWomen, myocardial infarction, and dementia in the very old
Aronson, M. K., Ooi, W. L., Morgenstern, H., Hafner, A., Masur, D., Crystal, H., Frishman, W. H., Fisher, D., & Katzman, R. (1990) · Neurology · doi:10.1212/wnl.40.7.1102 · Cited by 257
Grady, D., Yaffe, K., Kristof, M., Lin, F., Richards, C., & Barrett-Connor, E. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01270-6 · Cited by 222
Self-citationLow-Density Lipoprotein Cholesterol and the Risk of Dementia With Stroke
Moroney, J. T. (1999) · JAMA · doi:10.1001/jama.282.3.254 · Cited by 222
Evans, R. M., Emsley, C. L., Gao, S., Sahota, A., Hall, K. S., Farlow, M. R., & Hendrie, H. (2000) · Neurology · doi:10.1212/wnl.54.1.240 · Cited by 209
APOE genotype, plasma lipids, lipoproteins, and AD in community elderly
Romas, S. N., Tang, M.-X., Berglund, L., & Mayeux, R. (1999) · Neurology · doi:10.1212/wnl.53.3.517 · Cited by 169
Kalmijn, S., Feskens, E. J. M., Launer, L. J., & Kromhout, D. (1996) · Stroke · doi:10.1161/01.str.27.12.2230 · Cited by 160
ZIMETBAUM, P. J., Frishman, W. H., Ooi, W. L., Derman, M. P., Aronson, M., Gidez, L. I., & Eder, H. (1992) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.12.4.416 · Cited by 156
Harrison, R., & Ashton, C. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04268.x · Cited by 113
HMG-CoA reductase inhibitors (statins): A promising approach to stroke prevention
Hess, D. C., Demchuk, A. M., Brass, L. M., & Yatsu, F. M. (2000) · Neurology · doi:10.1212/wnl.54.4.790 · Cited by 113
Santanello, N. C., Barber, B., Applegate, W. B., Elam, J. T., Curtis, C., Hunninghake, D. B., Gordon, D. J., & For the CRISP Collaborative Study Group (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb00971.x · Cited by 101
Swan, G. E., LaRue, A., Carmelli, D., Reed, T. E., & Fabsitz, R. R. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530290058012 · Cited by 82
Kostis, J. B., Rosen, R. C., & Wilson, A. C. (1994) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1994.tb01971.x · Cited by 73
Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance
Richardson, G. S., Sullivan, J. P., Lee, R. M., Roth, T. G., Merlotti, L. A., & Roehrs, T. (1992) · Clinical Cardiology · doi:10.1002/clc.4960150607 · Cited by 70
Effects of treatment with lovastatin and pravastatin on daytime cognitive performance
Gengo, F. M., Cwudzinski, D., Kinkel, P. R., Block, G. A., Stauffer, L. A., & Lines, C. (1995) · Clinical Cardiology · doi:10.1002/clc.4960180406 · Cited by 53
Cited by
Midlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238
Self-citationBrain Cholesterol: Long Secret Life Behind a Barrier
Björkhem, I., & Meaney, S. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000120374.59826.1b · Cited by 1,044
The metabolic syndrome, inflammation, and risk of cognitive decline
Yaffe, K. (2004) · JAMA · doi:10.1001/jama.292.18.2237 · Cited by 1,025
“Stroke history 17 (1) 16 (2) 10 (3) 12 (4) .”
BackgroundInfluentialSelf-citationKinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Statin-Associated Side Effects
Thompson, P. D., Panza, G., Zaleski, A., & Taylor, B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.071 · Cited by 739
Metadata
- Authors
- Yaffe, K., Barrett-Connor, E., Lin, F., & Grady, D.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2002-03-01
- Volume
- 59
- Issue
- 3
- Pages
- 378
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2123457140
- Cited by
- 439
- References
- 30
- FWCI
- 26.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.